Elliott Targets Bio-Rad as Shares Continue to Struggle 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held at the Sofitel New York in New York, New York on September 27, 2016. Ocera’s presentation will take place in the Track 4 Orleans Room at 12:00 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
